Dermata Therapeutics (DRMA) Q4 2024 earnings summary

Executive summary

• Completed enrollment in XYNGARI Phase 3 STAR-1 clinical trial for moderate-to-severe acne; topline results expected by end of March 2025.

• Entered a collaboration with Revance to study DMT410 for axillary hyperhidrosis and other indications.

• Raised $7.8 million in 2024 and an additional $2.55 million in January 2025, extending operational runway into Q3 2025.

Financial highlights

• Cash and cash equivalents were $3.2 million as of December 31, 2024, down from $7.4 million at year-end 2023.

• Research and development expenses rose to $8.2 million in 2024 from $4.1 million in 2023, mainly due to increased clinical trial costs.

• General and administrative expenses increased to $4.3 million in 2024 from $4.0 million in 2023, primarily due to higher audit fees.

• Net loss for 2024 was $12.3 million, compared to $7.8 million in 2023.

• Net loss per share was $8.03 in 2024 versus $39.99 in 2023, reflecting a higher share count.

Outlook and guidance

• Topline results from the XYNGARI Phase 3 STAR-1 trial expected by end of March 2025.

• Plans to initiate the second Phase 3 STAR-2 trial for XYNGARI in moderate-to-severe acne, pending positive STAR-1 results.

• Current cash resources, including January 2025 financing, expected to fund operations into Q3 2025.